Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women

List of Included Studies (main publications)

52. Dobning H, Hofbauer LC, Viercek V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int. 2006;17(5):693-703.


69. Galesanu C, Lisnic N, Moisii L. Denosumab significantly increases BMD compared with alendronate in postmenopausal women. *Osteoporos Int.* 2015;S150.


28. Bolognese MA, Bone HG, Kendler DL, et al. Transitioning to denosumab leads to further increases in BMD throughout the skeleton in postmenopausal women who received 5 or more years of continuous alendronate therapy. Arthritis Rheum. 2011;63(Suppl 1).
38. Bone HG, Khandelwal DL, Bolognese MA, et al. Transitioning to denosumab leads to further increases in BMD throughout the skeleton in postmenopausal women who received 5 or more years of continuous alendronate therapy. Arthritis Rheum. 2011;63(12):4044-4045.


Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. *Calcif Tissue Int.* 2003;73(5):423-432.


100. Genant HK, Keaveny TM, Zapalowski C, et al. Cortical bone parameters at the hip in response to denosumab vs placebo and the clinical relevance of these changes in postmenopausal women with osteoporosis <75 and >=75 years old. *J Bone Miner Res*. 2013;28(Suppl 1).


Papapoulos S, Lewiecki EM, Dakin P, et al. Safety observations with three years of denosumab exposure: Comparison between subjects who received denosumab during FREEDOM and subjects who crossed over to denosumab during the FREEDOM Extension. J Bone Miner Res. 2015(Suppl 1).


Seeman E, Libanati C, Austin M, et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: A distinctive attribute of denosumab therapy. J Bone Miner Res. 2011(26).

Seeman E, Libanati C, Austin M, et al. The transitory PTH increase following denosumab administration is associated with reduced intracortical porosity: A distinctive characteristic of denosumab therapy. Osteoporos Int. 2012;23:S76-S77.
236. Thomas T, Cheung AM, Shane E, et al. Changes in lumbar spine QCT, DXA and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausal women with low bone mass. Osteoporos Int. 2014;25:S123.
242. Watts NB, Brown JP, Papapoulos S, et al. Safety observations with 3 years of denosumab exposure: Comparison between subjects who received denosumab during the pivotal 3-year trial.
and subjects who crossed over to denosumab during the extension. *Arthritis and Rheumatology*. 2015;67(Suppl 10).


### Additional records from grey literature

**Records from Clinicaltrials.gov trial registry database**

<table>
<thead>
<tr>
<th>Title</th>
<th>NCT Number</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older</td>
<td>NCT00132808</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00132808">https://ClinicalTrials.gov/show/NCT00132808</a></td>
</tr>
<tr>
<td>A Study of Monthly Risedronate for Osteoporosis</td>
<td>NCT00247273</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00247273">https://ClinicalTrials.gov/show/NCT00247273</a></td>
</tr>
<tr>
<td>Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis</td>
<td>NCT00404820</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00404820">https://ClinicalTrials.gov/show/NCT00404820</a></td>
</tr>
<tr>
<td>Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women</td>
<td>NCT00504166</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00504166">https://ClinicalTrials.gov/show/NCT00504166</a></td>
</tr>
<tr>
<td>Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover</td>
<td>NCT01249261</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01249261">https://ClinicalTrials.gov/show/NCT01249261</a></td>
</tr>
<tr>
<td>A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects</td>
<td>NCT00306189</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00306189">https://ClinicalTrials.gov/show/NCT00306189</a></td>
</tr>
<tr>
<td>Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method</td>
<td>NCT00386360</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00386360">https://ClinicalTrials.gov/show/NCT00386360</a></td>
</tr>
<tr>
<td>A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis</td>
<td>NCT00471237</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00471237">https://ClinicalTrials.gov/show/NCT00471237</a></td>
</tr>
<tr>
<td>Zoledronic Acid for Osteoporosis in the Elderly</td>
<td>NCT00558012</td>
<td><a href="https://ClinicalTrials.gov/show/NCT00558012">https://ClinicalTrials.gov/show/NCT00558012</a></td>
</tr>
<tr>
<td>Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy</td>
<td>NCT01512446</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01512446">https://ClinicalTrials.gov/show/NCT01512446</a></td>
</tr>
<tr>
<td>Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis</td>
<td>NCT01631214</td>
<td><a href="https://ClinicalTrials.gov/show/NCT01631214">https://ClinicalTrials.gov/show/NCT01631214</a></td>
</tr>
<tr>
<td>Denosumab China Phase III Study</td>
<td>NCT02014467</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02014467">https://ClinicalTrials.gov/show/NCT02014467</a></td>
</tr>
<tr>
<td>Title</td>
<td>Trial ID</td>
<td>Link</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets</td>
<td>NCT02063854</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02063854">https://ClinicalTrials.gov/show/NCT02063854</a></td>
</tr>
<tr>
<td>A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis</td>
<td>NCT02157948</td>
<td><a href="https://ClinicalTrials.gov/show/NCT02157948">https://ClinicalTrials.gov/show/NCT02157948</a></td>
</tr>
<tr>
<td>Zoledronic acid in patients with low bone mass.</td>
<td>CTRI/2017/05/008696</td>
<td><a href="http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18914">http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18914</a></td>
</tr>
<tr>
<td>Effect of Teriparatide, Alendronate, Zoledronic Acid, and combined effect of Teriparatide and Alendronate treatment of primary osteoporosis</td>
<td>IRCT201605169014N99</td>
<td><a href="http://en.irct.ir/trial/9537">http://en.irct.ir/trial/9537</a></td>
</tr>
<tr>
<td>The effect of zoledronate on marrow fat in osteoporotic elderly patients who have suffered a minimal trauma fracture.</td>
<td>ACTRN12611000082909</td>
<td><a href="http://www.anzctr.org.au/ACTRN12611000082909.aspx">http://www.anzctr.org.au/ACTRN12611000082909.aspx</a></td>
</tr>
<tr>
<td>Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis</td>
<td>JPRN-UMIN0000012193</td>
<td><a href="https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014251">https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014251</a></td>
</tr>
<tr>
<td>Study Description</td>
<td>Code</td>
<td>URL</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Comparative study of efficacy of minodronate, alendronate and risedronate in patients with osteoporosis</td>
<td>JPRN-UMIN000011407</td>
<td><a href="https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013355">Link</a></td>
</tr>
<tr>
<td>A multicentre, double-blind, randomised, active controlled, parallel group, noninferiority study comparing 75mg risedronate dosed on two consecutive days monthly with 5mg daily risedronate in the treatment of postmenopausal osteoporosis as assessed over 24 months - 2CDM</td>
<td>EUCTR2004-000486-35-GB</td>
<td><a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000486-35">Link</a></td>
</tr>
<tr>
<td>Study Title</td>
<td>Registration ID</td>
<td>Link</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Study in postmenopausal women with osteoporosis</td>
<td>CTRI/2018/05/013924</td>
<td><a href="http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=23200">http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=23200</a></td>
</tr>
<tr>
<td>The purpose of this study is to find out more about the efficacy and safety of denosumab produced by two different processes in postmenopausal women with osteoporosis.</td>
<td>EUCTR2013-001279-19-CZ</td>
<td><a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001279-19">https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001279-19</a></td>
</tr>
<tr>
<td>A multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of AMG 785 treatment in postmenopausal women with osteoporosis</td>
<td>per-089-12</td>
<td><a href="https://www.ins.gob.pe/ensayosclinicos/recuperarECPBNuevoEN.asp?numero=089-12">https://www.ins.gob.pe/ensayosclinicos/recuperarECPBNuevoEN.asp?numero=089-12</a></td>
</tr>
</tbody>
</table>